Literature DB >> 33277638

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.

Ioanna-Evdokia Galani1, Nikoletta Rovina2, Vicky Lampropoulou1, Vasiliki Triantafyllia1, Maria Manioudaki1, Eleftherios Pavlos1, Evangelia Koukaki3, Paraskevi C Fragkou4, Vasiliki Panou3, Vasiliki Rapti4, Ourania Koltsida5, Andreas Mentis6, Nikolaos Koulouris3, Sotirios Tsiodras4, Antonia Koutsoukou2, Evangelos Andreakos7,8.   

Abstract

A central paradigm of immunity is that interferon (IFN)-mediated antiviral responses precede pro-inflammatory ones, optimizing host protection and minimizing collateral damage1,2. Here, we report that for coronavirus disease 2019 (COVID-19) this paradigm does not apply. By investigating temporal IFN and inflammatory cytokine patterns in 32 moderate-to-severe patients with COVID-19 hospitalized for pneumonia and longitudinally followed for the development of respiratory failure and death, we reveal that IFN-λ and type I IFN production were both diminished and delayed, induced only in a fraction of patients as they became critically ill. On the contrary, pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6 and IL-8 were produced before IFNs in all patients and persisted for a prolonged time. This condition was reflected in blood transcriptomes wherein prominent IFN signatures were only seen in critically ill patients who also exhibited augmented inflammation. By comparison, in 16 patients with influenza (flu) hospitalized for pneumonia with similar clinicopathological characteristics to those of COVID-19 and 24 nonhospitalized patients with flu with milder symptoms, IFN-λ and type I IFN were robustly induced earlier, at higher levels and independently of disease severity, whereas pro-inflammatory cytokines were only acutely produced. Notably, higher IFN-λ concentrations in patients with COVID-19 correlated with lower viral load in bronchial aspirates and faster viral clearance and a higher IFN-λ to type I IFN ratio correlated with improved outcome for critically ill patients. Moreover, altered cytokine patterns in patients with COVID-19 correlated with longer hospitalization and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19, contributing to persistent viral presence, hyperinflammation and respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33277638     DOI: 10.1038/s41590-020-00840-x

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  152 in total

Review 1.  Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.

Authors:  Jintao Zhang; Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

2.  Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis.

Authors:  Rafaela Pires da Silva; João Ismael Budelon Gonçalves; Rafael Fernandes Zanin; Felipe Barreto Schuch; Ana Paula Duarte de Souza
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

3.  Combining immunomodulators and antivirals for COVID-19.

Authors:  Luke Y C Chen; Tien T T Quach
Journal:  Lancet Microbe       Date:  2021-06-02

Review 4.  Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.

Authors:  Shea A Lowery; Alan Sariol; Stanley Perlman
Journal:  Cell Host Microbe       Date:  2021-05-17       Impact factor: 21.023

5.  Downregulation of type III interferons in patients with severe COVID-19.

Authors:  Yosuke Fukuda; Tetsuya Homma; Hideki Inoue; Chisato Onitsuka; Hitoshi Ikeda; Yuiko Goto; Yoko Sato; Tomoyuki Kimura; Kuniaki Hirai; Shin Ohta; Mayumi Yamamoto; Sojiro Kusumoto; Shintaro Suzuki; Akihiko Tanaka; Hironori Sagara
Journal:  J Med Virol       Date:  2021-04-13       Impact factor: 20.693

6.  A Multimodal Approach for the Risk Prediction of Intensive Care and Mortality in Patients with COVID-19.

Authors:  Vasileios C Pezoulas; Konstantina D Kourou; Costas Papaloukas; Vassiliki Triantafyllia; Vicky Lampropoulou; Eleni Siouti; Maria Papadaki; Maria Salagianni; Evangelia Koukaki; Nikoletta Rovina; Antonia Koutsoukou; Evangelos Andreakos; Dimitrios I Fotiadis
Journal:  Diagnostics (Basel)       Date:  2021-12-28

Review 7.  Infection-induced inflammation from specific inborn errors of immunity to COVID-19.

Authors:  Cheng-Lung Ku; I-Ting Chen; Ming-Zong Lai
Journal:  FEBS J       Date:  2021-05-20       Impact factor: 5.622

Review 8.  The signal pathways and treatment of cytokine storm in COVID-19.

Authors:  Lan Yang; Xueru Xie; Zikun Tu; Jinrong Fu; Damo Xu; Yufeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-07-07

9.  Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients.

Authors:  Stéphanie Bibert; Nicolas Guex; Joao Lourenco; Thomas Brahier; Matthaios Papadimitriou-Olivgeris; Lauro Damonti; Oriol Manuel; Robin Liechti; Lou Götz; Jonathan Tschopp; Mathieu Quinodoz; Peter Vollenweider; Jean-Luc Pagani; Mauro Oddo; Olivier Hügli; Frédéric Lamoth; Véronique Erard; Cathy Voide; Mauro Delorenzi; Nathalie Rufer; Fabio Candotti; Carlo Rivolta; Noémie Boillat-Blanco; Pierre-Yves Bochud
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

Review 10.  COVID-19: Myths and Reality.

Authors:  Larisa V Kordyukova; Andrey V Shanko
Journal:  Biochemistry (Mosc)       Date:  2021-07       Impact factor: 2.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.